Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Treatment algorithm for pulmonary arterial hypertension].

Marius M Hoeper1

  • 1Abteilung Pneumologie, Medizinische Hochschule Hannover. hoeper.marius@mh-hannover.de

Herz
|June 21, 2005
PubMed
Summary

Recent advancements offer improved treatments for pulmonary arterial hypertension (PAH). Current guidelines, including novel prostanoids and targeted therapies, are summarized for better patient management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mental Disorders and Quality of Life in Patients With Pulmonary Arterial Hypertension Treated With Sotatercept.

Pulmonary circulation·2026
Same author

Sotatercept Safety and Efficacy in Intermediate- to Low-Risk Pulmonary Arterial Hypertension: A Pooled Analysis of PULSAR and STELLAR.

Chest·2026
Same author

The pleuroparenchymal fibroelastosis atlas reveals aberrant cell states and their zonation as an alternate roadmap to lung fibrosis.

Science advances·2026
Same author

B cell activating factor (BAFF) levels are associated with failed remission after 12 months of treatment with benralizumab and mepolizumab in severe asthma.

Respiratory research·2026
Same author

Initial triple combination therapy including sotatercept in a patient with severe idiopathic pulmonary arterial hypertension: a case report.

ERJ open research·2026
Same author

Post-Acute Sequelae Patients with Severe COVID-19 History Show a Prolonged Inflammatory, Vascular Injury Pattern.

European journal of immunology·2026

Area of Science:

  • Cardiovascular Medicine
  • Pulmonary Medicine
  • Pharmacology

Context:

  • Pulmonary arterial hypertension (PAH) is a severe condition with limited therapeutic options historically.
  • Significant progress has been made in understanding PAH pathogenesis, leading to innovative treatments.
  • Existing treatments include intravenous epoprostenol, novel prostanoids, endothelin receptor antagonists, and phosphodiesterase type 5 inhibitors.

Purpose:

  • To review and summarize current international guidelines for the diagnosis and management of pulmonary arterial hypertension (PAH).
  • To provide an overview of the latest therapeutic advancements and their place in clinical practice.
  • To highlight the evolving treatment landscape for PAH, including established and emerging therapies.

Summary:

  • Therapeutic options for PAH have substantially improved, with drugs like bosentan (endothelin receptor antagonist) recommended as first-line treatment.
  • Novel agents including sitaxsentan, ambrisentan, and sildenafil show promise, though some are still under investigation.
  • Combination therapy targeting multiple pathways is a future direction, pending large clinical trials.

Impact:

  • Current guidelines offer standardized treatment algorithms for PAH management.
  • The review synthesizes recent data to inform clinicians on optimal patient care strategies.
  • Advancements in PAH therapy aim to improve patient symptoms, hemodynamics, and long-term survival.

Related Experiment Videos